CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

Primary Care Considerations for the Diagnosis and Management of Migraine: Novel Strategies for the Treatment of Episodic Migraine

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Describe strategies to minimize the burden and suboptimal diagnosis/management of migraine in primary care settings, particularly among traditionally underserved populations
Assess the role of CGRP in the pathophysiology of migraine
Evaluate the role of CGRP receptor antagonists in the acute treatment of migraine and the preventive treatment of episodic migraine
Implement personalized treatment plans for episodic migraine across diverse patient populations for the provision of optimal care and outcomes

Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor).

Linda Davis, MD
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS
Shirley Kessel

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.

How many patients with episodic migraines do you see during a typical month?

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?

In the United States, Hispanic patients with headaches are _____ less likely to receive a migraine diagnosis compared to White patients with headaches.

Which of the following is expressed in both the peripheral and central nervous systems, including the trigeminovascular pathways, and is elevated during migraine attacks?

Which of the following is an intranasal formulation for the acute treatment of migraine in adults that received FDA approval based on statistically superior results of pain freedom and freedom from the most bothersome symptom at two hours post-dose?

Which of the following is an oral medication indicated for both the acute treatment of migraine and prevention of episodic migraine in adults?

How confident are you now in your ability to implement recent data, newer therapeutic strategies, and guideline-directed care in clinical practice to minimize episodic migraine risk and improve patient outcomes?

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often (select all that apply):